> Chemicals & Drugs > Amino Acid > METTL14 protein, human

METTL14 protein, human

Q: What are the key functions of the METTL14 protein in humans?

The METTL14 protein is a crucial methyltransferase enzyme that plays a vital role in the post-transcriptional modification of RNA. It catalyzes the addition of methyl groups to adenosine residues, a process known as N6-methyladenosine (m6A) modification. METTL14 is a core component of the m6A methyltransferase complex, which is involved in diverse biological processes, such as mRNA stability, translation, and degradation, as well as the regulation of gene expression.

Q: How does METTL14 dysregulation impact human health?

Dysregulation of the METTL14 protein has been implicated in various diseases, including cancer and neurological disorders. Alterations in METTL14 expression or activity can disrupt the delicate balance of m6A modification, leading to downstream effects on RNA processing and gene expression that contribute to the development and progression of these diseases.

Q: What are some common variations or types of the METTL14 protein?

While there is typically only one predominant form of the METTL14 protein in humans, researchers may encounter different isoforms or variants depending on the specific experimental system or disease context they are studying. These variations can arise from alternative splicing, mutations, or post-translational modifications, and may exhibit distinct functional properties or expression patterns.

Q: How can PubCompare.ai assist in METTL14 protein research?

PubCompare.ai is a cutting-edge AI platform that can help optimize your METTL14 protein research. The platform allows you to efficiently screen protocol literature, leveraging AI to pinpoint critical insights. PubCompare.ai can help researchers identify the most effective protocols related to METTL14 protein, human for their specific research goals. The platform's AI-driven analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accracy.

Q: What are some common applications of the METTL14 protein in research?

Researchers studying the METTL14 protein often focus on understanding its role in various biological processes, such as RNA modification, gene expression regulation, and cellular homeostasis. Additionally, METTL14 is a target of interest in the context of disease research, particularly in cancer and neurological disorders, where its dysregulation has been implicated. By leveraging cutting-edge tools like PubCompare.ai, researchers can optimize their METTL14 protein experiments and enhance the reproducibility and accracy of their findings.

METTL14 is a methyltransferase enzyme that plays a crucial role in the post-transcriptional modification of RNA.
It catalyzes the addition of methyl groups to adenosine residues, a process known as N6-methyladenosine (m6A) modification.
METTL14 is a core component of the m6A methyltransferase complex, which also includes METTL3 and other regulatory subunits.
This enzyme is involved in diverse biological processes, such as mRNA stability, translation, and degradation, as well as in the regulation of gene expression.
Dysregulation of METTL14 has been implicated in various diseases, including cancer and neurological disorders.
Researchers studying the METTL14 protein can leveragge cutting-edge AI platforms, such as PubCompare.ai, to optimize their experiments and enhance the reproducibility and accuracy of their findings.

Most cited protocols related to «METTL14 protein, human»

M6A Modification Patterns Analysis

Cited 26 times

Owing to the few m⁶A regulators detected by Illumina HumanRef-8 WG-DASL v3.0 platform, we did not include GSE26253 cohort for clustering analysis. A total of 21 regulators were extracted from five integrated GEO datasets for identifying different m⁶A modification patterns mediated by m⁶A regulators. These 21 m⁶A regulators included 8 writers (METTL3, METTL14, RBM15, RBM15B, WTAP, KIAA1429, CBLL1, ZC3H13), 2 erasers (ALKBH5, FTO) and 11 readers (YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3, IGF2BP1, HNRNPA2B1, HNRNPC, FMR1, LRPPRC, ELAVL1). Unsupervised clustering analysis was applied to identify distinct m⁶A modification patterns based on the expression of 21 m⁶A regulators and classify patients for further analysis. The number of clusters and their stability were determined by the consensus clustering algorithm [25 (link)]. We used the ConsensuClusterPlus package to perform the above steps and 1000 times repetitions were conducted for guaranteeing the stability of classification [26 (link)].

Zhang B., Wu Q., Li B., Wang D., Wang L, & Zhou Y.L. (2020). m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Molecular Cancer, 19, 53.

Publication 2020

METTL3 protein, human METTL14 protein, human Patients RBM15 protein, human

In vitro Methyltransferase Activity Assay

Cited 17 times

In vitro methyltransferase activity assay was performed in a standard 50 μL of reaction mixture containing the following components: 0.15 nmol RNA probe, 0.15 nmol each recombinant protein (single METTL3, METTL14, WTAP, or their combinations with a molar ratio of 0.15 nmol/0.15 nmol for two components, 0.8 mM d₃-SAM, 80 mM KCl, 1.5 mM MgCl₂, 0.2 U μL⁻¹ RNasin, 10 mM DTT, 4% glycerol, and 15 mM HEPES (pH 7.9). Prior to the reaction, the RNA probes were annealed with a program of (i) 90 °C for 3 min, and (ii) −2 °C/cycle for 40 cycles within 30 min.
The reaction was incubated at 16 °C for 12 h. The resultant RNA was recovered by phenol/chloroform (low pH) extraction followed by ethanol precipitation, and digested by nuclease P1 and alkaline phosphatase for QQQ LC-MS/MS analysis. The nucleosides were quantified by using the nucleoside to base ion mass transitions of 285 to 153 (d₃-m⁶A) and 284 to 152 (G). G served as an internal control to calculate the amount of RNA probe in each reaction mixture.

Liu J., Yue Y., Han D., Wang X., Fu Y., Zhang L., Jia G., Yu M., Lu Z., Deng X., Dai Q., Chen W, & He C. (2013). A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nature chemical biology, 10(2), 93-95.

Publication 2013

Alkaline Phosphatase Biological Assay Chloroform Ethanol Glycerin HEPES Magnesium Chloride Methyltransferase METTL3 protein, human METTL14 protein, human Molar Nucleosides Phenol Recombinant Proteins RNA Probes Tandem Mass Spectrometry

Measuring mRNA Decay Kinetics

Cited 9 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017

Cells Dactinomycin GATA2 Deficiency METTL14 protein, human mRNA Decay mRNA Degradation Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger Transcription, Genetic

METTL3/14/4 and WTAP Knockdown Assay

Cited 9 times

Human HeLa cell line was grown in DMEM (Gibco, 11965) media supplemented with 10% FBS and 1% 100× Pen Strep (Gibco, 15140). Human 293FT cell line was grown in DMEM (Gibco, 11995) media supplemented with 10% FBS and 1% 100× Pen Strep. METTL3, METTL14, METTL4, and WTAP siRNAs were purchased from QIAGEN with sequences shown in Supplementary Table 1. Transfection was achieved by using Lipofectamine RNAiMAX (Invitrogen) for siRNA, or Lipofectamine 2000 (Invitrogen) for the plasmid following the manufacturer’s protocols.

Publication 2013

Cell Lines HeLa Cells Homo sapiens Lipofectamine lipofectamine 2000 METTL3 protein, human METTL14 protein, human Plasmids RNA, Small Interfering Streptococcal Infections Transfection

Transcriptome Profiling and m6A-Related lncRNAs in KIRC

Cited 7 times

As the flow chart of the study shown in Figure S1, we downloaded Transcriptome profiling data in fragment per kilobase method (FPKM) format of 530 KIRC patients from TCGA data portal (https://portal.gdc.cancer.gov/). Subsequently, these data were collated and annotated, and then collapsed into protein-coding genes and long non-coding RNAs employing the Ensembl human genome browser (http://asia.ensembl.org/info/data/index.html) using the Perl program (16 (link)). And 14,142 lncRNAs were identified. Then, the differential analysis of these lncRNAs was performed by the “limma” package in R 4.0.3 (logFC > 1 or<-1, p < 0.05), and 4,492 significantly differential lncRNAs were identified. In addition, 35 m6A-related genes were obtained from published articles (8 (link), 17 (link)), and the expression matrixes were extracted from transcriptome profiling datasets, including regulators on writers [KIAA1429 (VIRMA), METTL3, METTL14, WTAP, RBM15, RBM15B, METTL16, ZC3H13, and PCIF1], readers [TRMT112, ZCCHC4, NUDT21 (CPSF5), CPSF6, CBLL1 (HAKAI), SETD2, HNRNPC, HNRNPG (RBMX), HNRNPA2B1, IGF2BP1, IGF2BP2, IGF2BP3, YTHDC1, YTHDF1, YTHDF2, YTHDF3, YTHDC2, SRSF3, SRSF10, XRN1, FMR1 (FMRP), NXF1, and PRRC2A], and erasers (FTO, ALKBH5, and ALKBH3). The differential analysis was also performed by the “limma” package in R software and 25 m6A-related genes were confirmed to be significantly different (p < 0.05, Figure S2). Then, Pearson correlation analysis between these lncRNAs and 25 m6A-related genes was performed, and 753 m6A-related lncRNAs were identified (cor > 0.5 or <−0.5, p < 0.05). The clinicopathological data were downloaded from the TCGA dataset, excluding those with survival time <30 days or unknown (n = 17), and those with unclear specific information including stage (n = 3), tumor grade (n = 3), and AJCC M stage (n = 3). Subsequently, we merged lncRNAs expression data with clinical data. Ultimately, a total of 505 cases were included in the study.

Yu J., Mao W., Sun S., Hu Q., Wang C., Xu Z., Liu R., Chen S., Xu B, & Chen M. (2021). Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 11, 663263.

Publication 2021

Division Phase, Cell Fragile X Mental Retardation Protein Gene Products, Protein Genes Genome, Human hSet2 protein, human IGF2BP2 protein, human IGF2BP3 protein, human Malignant Neoplasms METTL3 protein, human METTL14 protein, human Neoplasms RBM15 protein, human RNA, Long Untranslated SRSF3 protein, human XRN1 protein, human

Most recents protocols related to «METTL14 protein, human»

Exploring m6A-related Genes in HCC

The correlation between 19 CRGs and m6A-related genes expression and prognostic in 371 HCC samples was analyzed by R (4.0.3) packages “ggplot2.” The difference in m6A-related gene expression between C1 group (N = 252) and C2 group (N = 119) was investigated. The m6A-related genes analyzed included METTL3, YTHDC1, YTHDC2, METTL14, RBM15, RBM15B, IGF2BP1, IGF2BP2, IGF2BP3, VIRMA, WTAP, YTHDF1, YTHDF2, YTHDF3, ZC3H13, HNRNPA2B1, HNRNPC, RBMX, FTO, and ALKBH5.

Qin H., Sheng W., Zhang G., Yang Q., Yao S., Yue Y., Zhang P., Zhu Y., Wang Q., Chen Y., Zeng H., Weng J., Yu F, & Yang J. (2023). Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. Frontiers in Genetics, 14, 1094793.

Publication 2023

Gene Expression Genes IGF2BP2 protein, human IGF2BP3 protein, human METTL3 protein, human METTL14 protein, human RBM15 protein, human

Targeted Silencing of m6A Regulators

Short interfering RNAs targeting METTL3, CTSL, IGF2BP2, METTL14, and RBM15 mRNAs, and a negative control siRNA, were designed by RiboBio. Co, Ltd. The siRNA sequences are listed in Table S2. Short interfering RNA transfection was achieved using Lipofectamine 3000 (Invitrogen) following the manufacturer's instructions. A plasmid directing METTL3 overexpression (Guangzhou FulenGen Co, Ltd.) was transfected into 293FT cells to produce lentivirus vectors. The cells were then infected with the lentivirus in the presence of polybrene and selected for 1 week with 2–4 μg/ml puromycin. Plasmids for CTSL and CTSL with WT or mutant m6A region were purchased from Guangzhou Da Hong.

Liu P., Ju M., Zheng X., Jiang Y., Yu X., Pan B., Luo R., Jia W, & Zheng M. (2023). Methyltransferase‐like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6‐methyladenosine‐dependent manner. Cancer Science, 114(3), 837-854.

Publication 2023

Cells Cloning Vectors CTSL protein, human IGF2BP2 protein, human Lentivirus Lipofectamine METTL3 protein, human METTL14 protein, human Plasmids Polybrene Puromycin RBM15 protein, human RNA, Messenger RNA, Small Interfering Transfection

Western Blot Analysis of RNA-Binding Proteins

Proteins were lysed in radioimmunoprecipitation assay buffer containing protease inhibitors (Beyotime Biotechnology), separated by electrophoresis and transferred to PVDF membranes (Bio‐Rad). After overnight incubation with primary Abs (anti‐METTL3 [1:1000 dilution, ab195352; Abcam], anti‐CTSL [1:500 dilution, 66,914‐1‐lg; Proteintech], anti‐insulin‐like growth factor 2 mRNA‐binding protein [IGF2BP2] [1:1000 dilution, ab128175; Abcam], anti‐METTL14 [1:1000 dilution, ab220030’ Abcam], anti‐RNA binding motif protein 15 [RBM15] [1:1000 dilution; PTM‐6163; Jingjie PTM BioLab], and anti‐β‐actin [1:5000 dilution; 4970S; Cell Signaling Technology]), the membranes were incubated with a HRP‐conjugated secondary Ab (1:5000 dilution, 7076S, 7074S; Cell Signaling Technology). The immunoreactions were visualized using the ECL Plus substrate (Merck Millipore). β‐Actin was used for normalization.

Publication 2023

Actins Buffers CTSL protein, human Electrophoresis IGF2BP2 protein, human Insulin-Like Growth Factor Binding Protein 2 METTL3 protein, human METTL14 protein, human polyvinylidene fluoride Protease Inhibitors Proteins Radioimmunoprecipitation Assay RBM15 protein, human RNA, Messenger Technique, Dilution Tissue, Membrane

Analysis of m6A Regulators in Myasthenia Gravis

The dataset of mRNA expression profile under accession number GSE85452 [15 (link)], which included 13 MG samples and 12 healthy samples, was downloaded from Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) by “GEOquery” R package. The mRNA expression profile of CD14 monocytes was performed on peripheral blood of all samples using Illumina HumanHT-12 V4.0 expression beadchip. Gene probes were annotated as gene symbols based on platform annotation file. Gene probes, having multiple matching gene symbols or without matching gene symbols, were excluded. The median value was selected as the expression value of duplicate gene symbols.
We manually curated m6A RNA methylation modification regulators through reviewing related publications. A gene list of m6A modification regulators was obtained, including 8 writers (METTL3, METTL14, WTAP, KIAA1429, RBM15, RBM15B, CBLL1, and ZC3H13), 2 erasers (FTO and ALKBH5) and 13 readers (YTHDF1, YTHDF2, YTHDF3, YTHDC1, YTHDC2, HNRNPC, HNRNPA2B1, IGF2BP1, IGF2BP2, IGF2BP3, FMR1, ELAVL1, and LRPPRC).

Li S., Liu H., Ruan Z., Guo R., Sun C., Tang Y., Huang X., Gao T., Hao S., Li H., Song N., Su Y., Ning F., Li Z, & Chang T. (2023). Landscape analysis of m6A modification regulators related biological functions and immune characteristics in myasthenia gravis. Journal of Translational Medicine, 21, 166.

Publication 2023

BLOOD Genes Genes, Duplicate Genes, vif IGF2BP2 protein, human IGF2BP3 protein, human Methylation METTL3 protein, human METTL14 protein, human Monocytes Multiple Birth Offspring RBM15 protein, human RNA, Messenger

Cardiac Muscle Protein Expression Analysis

Cardiac muscle tissue was harvested and placed in RIPA lysis buffer containing 1 mM phenylmethanesulfonyl fluoride. Protein samples were separated using 10% and 15% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Biotech Well). The membranes were blocked with 5% BSA in TBST for 2 h and incubated overnight at 4 °C with the following primary antibodies: anti-ALKBH5 (ab195377, Abcam), anti-Mettl3 (ab195352, Abcam), anti-Mettl14 (ab252562, Abcam), anti-FTO (ab280081, Abcam), anti-BAX (ab3191, Abcam), anti-BCL-2 (ab196495, Abcam), anti-cleaved caspase3 (ab214430, Abcam), anti-Raf1 (A0223, Abclone), anti-phospho-Raf1-S259 (AP1012, Abclone), anti-p44/42 ERK1/2 (4370S, CST), anti-FLAG (Abcam, ab1162), anti-Rasal3 (NBP2-83439, Novusbio), and anti-β-actin (4970S, CST). The samples were then incubated at room temperature (24 °C) for 1.5 h with horseradish peroxidase-conjugated secondary antibody. Proteins were detected using Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA) and gel images were captured using ImageQuant LAS 4000 Mini Biomolecular Imager (GE Healthcare, Barrington, IL, USA).

Gao R.F., Yang K., Qu Y.N., Wei X., Shi J.R., Lv C.Y., Zhao Y.C., Sun X.L., Xu Y.J, & Yang Y.Q. (2023). m6A demethylase ALKBH5 attenuates doxorubicin-induced cardiotoxicity via posttranscriptional stabilization of Rasal3. iScience, 26(3), 106215.

Publication 2023

Actins Antibodies BCL2 protein, human Buffers Caspase 3 Immobilon Immunoglobulins METTL3 protein, human METTL14 protein, human mitogen-activated protein kinase 3, human Myocardium Phenylmethylsulfonyl Fluoride polyvinylidene fluoride Proteins Radioimmunoprecipitation Assay Raf1 protein, human SDS-PAGE Tissue, Membrane

Top products related to «METTL14 protein, human»

Trizol reagent by Thermo Fisher Scientific

Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand

TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.

Lipofectamine 3000 by Thermo Fisher Scientific

Sourced in United States, China, Germany, Japan, United Kingdom, France, Canada, Italy, Australia, Switzerland, Denmark, Spain, Singapore, Belgium, Lithuania, Israel, Sweden, Austria, Moldova, Republic of, Greece, Azerbaijan, Finland

Lipofectamine 3000 is a transfection reagent used for the efficient delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into a variety of mammalian cell types. It facilitates the entry of these molecules into the cells, enabling their expression or silencing.

Pvdf membrane by Merck Group

Sourced in United States, Germany, China, United Kingdom, Morocco, Ireland, France, Italy, Japan, Canada, Spain, Switzerland, New Zealand, India, Hong Kong, Sao Tome and Principe, Sweden, Netherlands, Australia, Belgium, Austria

PVDF membranes are a type of laboratory equipment used for a variety of applications. They are made from polyvinylidene fluoride (PVDF), a durable and chemically resistant material. PVDF membranes are known for their high mechanical strength, thermal stability, and resistance to a wide range of chemicals. They are commonly used in various filtration, separation, and analysis processes in scientific and research settings.

Lipofectamine 2000 by Thermo Fisher Scientific

Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco

Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.

Ab195352 by Abcam

Sourced in United Kingdom, United States, China

Ab195352 is a lab equipment product from Abcam. It is a device used for the detection and measurement of specific molecules or analytes in a sample.

Hpa038002 by Merck Group

Sourced in United States, Germany

HPA038002 is a laboratory instrument designed for the purpose of protein analysis. It is a versatile and reliable tool used in various research and clinical settings. The core function of this product is to facilitate the separation, identification, and quantification of protein samples. This equipment employs advanced techniques to enable accurate and efficient protein analysis, supporting a wide range of research and diagnostic applications.

Mettl14 by Merck Group

Sourced in China

METTL14 is a methyltransferase enzyme that catalyzes the methylation of specific RNA substrates. It is involved in the post-transcriptional modification of RNA molecules. The core function of METTL14 is to facilitate the addition of methyl groups to RNA, which can influence RNA stability, localization, and translation.

Ab220030 by Abcam

Sourced in United States, United Kingdom

Ab220030 is an antibody product manufactured by Abcam. It is a primary antibody that can be used for various research applications. The core function of this product is to bind to and detect the target antigen, but the specific intended use is not provided in this factual description.

Lipofectamine rnaimax by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Japan, France, Canada, Switzerland, Denmark, Belgium, Italy, Australia, Singapore, Spain, Colombia, Sweden, Netherlands, New Zealand, Poland, Pakistan, Lithuania

Lipofectamine RNAiMAX is a transfection reagent designed for efficient delivery of small interfering RNA (siRNA) and short hairpin RNA (shRNA) into a wide range of cell types. It is a cationic lipid-based formulation that facilitates the uptake of these nucleic acids into the target cells.

Mettl3 by Proteintech

Sourced in United States, China

METTLER3 is a protein that catalyzes the addition of methyl groups to RNA molecules. It plays a role in mRNA processing and stability.

What are the key functions of the METTL14 protein in humans?

The METTL14 protein is a crucial methyltransferase enzyme that plays a vital role in the post-transcriptional modification of RNA. It catalyzes the addition of methyl groups to adenosine residues, a process known as N6-methyladenosine (m6A) modification. METTL14 is a core component of the m6A methyltransferase complex, which is involved in diverse biological processes, such as mRNA stability, translation, and degradation, as well as the regulation of gene expression.

How does METTL14 dysregulation impact human health?

What are some common variations or types of the METTL14 protein?

While there is typically only one predominant form of the METTL14 protein in humans, researchers may encounter different isoforms or variants depending on the specific experimental system or disease context they are studying. These variations can arise from alternative splicing, mutations, or post-translational modifications, and may exhibit distinct functional properties or expression patterns.

How can PubCompare.ai assist in METTL14 protein research?

PubCompare.ai is a cutting-edge AI platform that can help optimize your METTL14 protein research. The platform allows you to efficiently screen protocol literature, leveraging AI to pinpoint critical insights. PubCompare.ai can help researchers identify the most effective protocols related to METTL14 protein, human for their specific research goals. The platform's AI-driven analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accracy.

What are some common applications of the METTL14 protein in research?

Researchers studying the METTL14 protein often focus on understanding its role in various biological processes, such as RNA modification, gene expression regulation, and cellular homeostasis. Additionally, METTL14 is a target of interest in the context of disease research, particularly in cancer and neurological disorders, where its dysregulation has been implicated. By leveraging cutting-edge tools like PubCompare.ai, researchers can optimize their METTL14 protein experiments and enhance the reproducibility and accracy of their findings.

More about "METTL14 protein, human"

Discover the crucial role of METTL14, a methyltransferase enzyme, in post-transcriptional RNA modification.
This core component of the m6A methyltransferase complex, which includes METTL3 and other regulatory subunits, is essential for diverse biological processes like mRNA stability, translation, and gene expression regulation.
Leverage cutting-edge AI platforms like PubCompare.ai to optimize your METTL14 protein research and enhance reproducibility and accuracy.
METTL14 catalyzes the addition of methyl groups to adenosine residues, a process known as N6-methyladenosine (m6A) modification.
This epigenetic mark plays a pivotal role in mRNA processing and fate, impacting stability, translation, and degradation.
Dysregulation of METTL14 has been implicated in various diseases, including cancer and neurological disorders.
Streamline your METTL14 experiments with PubCompare.ai's advanced tools.
Locate the best protocols from literature, pre-prints, and patents through AI-driven comparisons, leveraging resources like TRIzol reagent, Lipofectamine 3000, PVDF membranes, Lipofectamine 2000, Ab195352, HPA038002, Ab220030, and Lipofectamine RNAiMAX.
Enhance your research by integrating the latest findings on the METTL14 protein and its interplay with METTL3.
Optimize your METTL14 studies and uncover novel insights with the help of PubCompare.ai's cutting-edge AI platform.
Streamline your experiments, improve reproducibility, and elevate the accuracy of your findings in the dynamic field of epitranscriptomics and RNA modification.